ALKERMES | ALKS - Cash And Equivalent


ALKERMES reported $511.53M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
AbbVie USD 6.57B 2.82B Jun/2026
Acadia Pharmaceuticals USD 851.46M 31.77M Mar/2026
ALKERMES USD 511.53M 159.98M Jun/2026
Amgen USD 12.04B 2.91B Mar/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 2.22B 910.76M Mar/2026
Bristol-Myers Squibb USD 8.72B 852M Jun/2026
Coherus Biosciences USD 88.88M 14.47M Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Heron Therapeutics USD 26.12M 2.53M Mar/2026
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Malin Corporation EUR 62.1M 26.4M Dec/2024
Merck USD 5.33B 9.24B Mar/2026
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Nektar Therapeutics USD 149.58M 134.46M Mar/2026
Neurocrine Biosciences USD 332.4M 65.9M Jun/2026
Otsuka Holdings JPY 534.64B 123.53B Dec/2025
Pfizer USD 976M 727M Jun/2026
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026